First Trust Advisors
VERV

First Trust Advisors’s Verve Therapeutics VERV Stock Holding History

First Trust Advisors’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-45,394
Closed -$1.56M – 2568
2022
Q3 		$1.56M Buy
+45,394
New +$1.45M ﹤0.01% 1813

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

First Trust Advisors's VERV Position: Q4 2022 in Review

First Trust Advisors sold out of Verve Therapeutics (VERV) in Q4 2022, closing a stake of 45,394 shares — an estimated $1.56M sold.

First Trust Advisors first reported a position in VERV in Q3 2022 and held it in 1 quarter. The position peaked at $1.56M in Q3 2022. 123 funds tracked by Wall St. Rank hold VERV as of Q4 2022.

  • First Trust Advisors reported no remaining Verve Therapeutics position as of Q4 2022 after selling out during the quarter.
  • First Trust Advisors sold 45,394 Verve Therapeutics shares in Q4 2022, an estimated $1.56M.
  • First Trust Advisors first reported a position in Verve Therapeutics in Q3 2022 and held it in 1 quarter.
  • First Trust Advisors's Verve Therapeutics position peaked at $1.56M in Q3 2022.
  • 123 funds tracked by Wall St. Rank held Verve Therapeutics as of Q4 2022.

Based on First Trust Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.